Goldman Sachs Group Inc Roivant Sciences Ltd. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,201,335 shares of ROIV stock, worth $48.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,201,335
Previous 1,498,916
180.29%
Holding current value
$48.6 Million
Previous $15.8 Million
181.1%
% of portfolio
0.01%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ROIV
# of Institutions
308Shares Held
496MCall Options Held
989KPut Options Held
1.15M-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$826 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$800 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$772 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$409 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$339 Million0.02% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.15B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...